Enhanced Compounds for Treating Coronavirus Infections

Improved compounds and compositions for treating coronavirus-associated diseases, offering enhanced efficacy and reduced inflammation.

The original patent disclosed compounds and compositions for treating coronavirus-associated diseases. However, these compounds had limitations in terms of efficacy and potential side effects. The new inventive concept addresses these limitations by introducing novel compounds and compositions that provide enhanced treatment outcomes and reduced inflammation.

The new inventive concept involves administering compounds represented by Formula I, which are further enhanced by co-administering anti-inflammatory agents, targeting the compounds to the site of protease activity using carrier molecules, or combining them with saccharide or peptide moieties as targeting agents. Additionally, the inventive concept includes pharmaceutical compositions, methods for reducing mortality and signs of inflammation, and kits for treating coronavirus-associated diseases. These enhancements improve the efficacy and safety of the original compounds, providing better treatment outcomes for patients.

The new claims introduce novel combinations of compounds and anti-inflammatory agents, targeting mechanisms, and pharmaceutical compositions that are not obvious from the original patent. These enhancements provide a significant improvement over the prior art, making the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include varying the structure of the compounds, using different carrier molecules or targeting agents, or combining the compounds with other therapeutic agents. These variations would ensure broad conceptual coverage and provide opportunities for further development and improvement.

The enhanced compounds and compositions for treating coronavirus-associated diseases have significant commercial potential in the pharmaceutical industry, particularly in the areas of infectious disease treatment and pandemic response. The target market includes hospitals, clinics, and research institutions involved in treating and studying coronavirus-associated diseases.